Abstract
Introduction
Fuelled by the pandemic flu threat, the influenza market has expanded rapidly
in recent years. This growing commercial opportunity has encouraged companies
to develop new technologies and increase manufacturing capacity for influenza
vaccines and antivirals. The H1N1 pandemic will stimulate further growth, but
also confronts industry and public health stakeholders with new challenges.
Key reasons to purchase this research
- Review the clinical and commercial factors driving new product decisions
in influenza vaccines and the strategies of key players in the market
- Size the market with patient-based scenario forecasts of the seasonal
vaccines market and a thorough analysis of the vaccine and antiviral pipeline
- Understand concerns, unmet needs and future opportunities in influenza
prevention and therapy
| 
View Cart
